Triplebar announced $20M in new funding to expand its product portfolio in food and biopharmaceuticals. Synthesis Capital led the round, with participation from Essential Capital, Stray Dog Capital, iSelect Fund, and existing major investor The Production Board

Triplebar's Hyper-Throughput™ screening platform acts as a 'microprocessor for biology,' integrating hardware, software, biology and biochemistry to miniaturize and accelerate evolution. Triplebar and its commercial partners use the platform to develop biological systems for manufacturing low-cost, low-footprint animal proteins to replace traditional animal sources, improving the performance of animal cell lines for cellular meat products, and discovering novel therapeutic biologic drug candidates for addressing major human health challenges.